Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ultragenyx Pharmaceutical (RARE) Change in Cash: 2012-2024

Historic Change in Cash for Ultragenyx Pharmaceutical (RARE) over the last 13 years, with Dec 2024 value amounting to -$35.2 million.

  • Ultragenyx Pharmaceutical's Change in Cash rose 107.89% to $26.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $54.5 million, marking a year-over-year decrease of 33.23%. This contributed to the annual value of -$35.2 million for FY2024, which is 143.08% down from last year.
  • As of FY2024, Ultragenyx Pharmaceutical's Change in Cash stood at -$35.2 million, which was down 143.08% from $81.8 million recorded in FY2023.
  • Over the past 5 years, Ultragenyx Pharmaceutical's Change in Cash peaked at $290.1 million during FY2020, and registered a low of -$416.7 million during FY2021.
  • In the last 3 years, Ultragenyx Pharmaceutical's Change in Cash had a median value of -$35.2 million in 2024 and averaged -$41.8 million.
  • As far as peak fluctuations go, Ultragenyx Pharmaceutical's Change in Cash tumbled by 243.67% in 2021, and later soared by 147.56% in 2023.
  • Over the past 5 years, Ultragenyx Pharmaceutical's Change in Cash (Yearly) stood at $290.1 million in 2020, then plummeted by 243.67% to -$416.7 million in 2021, then skyrocketed by 58.73% to -$172.0 million in 2022, then spiked by 147.56% to $81.8 million in 2023, then slumped by 143.08% to -$35.2 million in 2024.